Key stats
About Tema Oncology ETF
Home page
Inception date
Aug 15, 2023
Structure
Open-Ended Fund
Replication method
Physical
Dividend treatment
Distributes
Distribution tax treatment
Qualified dividends
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
Tema Global Ltd.
Distributor
Foreside Fund Services LLC
ISIN
US87975E7013
CANC aims for long-term growth by investing in companies that derive most of their revenue from the field of oncology. This includes large pharmaceutical firms, medical device companies and healthcare service providers whose primary focus is cancer treatment and management. The fund adopts a comprehensive analysis approach, utilizing internal research, external sources, and thematic investing strategies to identify promising investment opportunities within the oncology sector. The portfolio typically consists of 15 to 100 companies that meet minimum market capitalization and trading liquidity requirements. While CANC may hold stocks of companies globally, a substantial portion of its assets are anticipated to be allocated in the US and Europe. Additionally, ESG factors are incorporated in the funds investment process for smart risk management and return optimization. Being actively managed, the portfolio manager has full discretion to make buy, sell, and hold decisions.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.40%
Health Technology98.18%
Health Services0.80%
Technology Services0.42%
Bonds, Cash & Other0.60%
Mutual fund0.52%
Cash0.08%
Stock breakdown by region
North America65.72%
Europe28.02%
Asia6.25%
Latin America0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
CANC invests in stocks. The fund's major sectors are Health Technology, with 98.18% stocks, and Health Services, with 0.80% of the basket. The assets are mostly located in the North America region.
CANC top holdings are Revolution Medicines, Inc. and Eli Lilly and Company, occupying 5.85% and 4.74% of the portfolio correspondingly.
CANC last dividends amounted to 0.23 USD. The year before, the issuer paid 0.50 USD in dividends, which shows a 118.47% decrease.
CANC assets under management is 73.84 M USD. It's risen 13.76% over the last month.
CANC fund flows account for 25.00 M USD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
Yes, CANC pays dividends to its holders with the dividend yield of 1.80%. The last dividend (Dec 12, 2024) amounted to 0.73 USD. The dividends are paid annually.
CANC shares are issued by Dawn Global Topco Ltd. under the brand Tema. The ETF was launched on Aug 15, 2023, and its management style is Active.
CANC expense ratio is 0.75% meaning you'd have to pay 0.75% of your investment to help manage the fund.
CANC follows the No Underlying Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
CANC invests in stocks.
CANC price has risen by 8.22% over the last month, and its yearly performance shows a −5.82% decrease. See more dynamics on CANC price chart.
NAV returns, another gauge of an ETF dynamics, showed a 7.90% increase in three-month performance and has decreased by −1.28% in a year.
NAV returns, another gauge of an ETF dynamics, showed a 7.90% increase in three-month performance and has decreased by −1.28% in a year.
CANC trades at a premium (0.27%) meaning the ETF is trading at a higher price than the calculated NAV.